Home Cart Sign in  
Chemical Structure| 223488-57-1 Chemical Structure| 223488-57-1

Structure of Evatanepag
CAS No.: 223488-57-1

Chemical Structure| 223488-57-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Evatanepag is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.

Synonyms: CP-533536 free acid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Evatanepag

CAS No. :223488-57-1
Formula : C25H28N2O5S
M.W : 468.57
SMILES Code : CC(C)(C)C(C=C1)=CC=C1CN(S(C2=CN=CC=C2)(=O)=O)CC3=CC(OCC(O)=O)=CC=C3
Synonyms :
CP-533536 free acid
MDL No. :MFCD09833940
InChI Key :WOHRHWDYFNWPNG-UHFFFAOYSA-N
Pubchem ID :9890801

Safety of Evatanepag

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Evatanepag

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RAW 264.7 macrophages 25 μM 24 hours To evaluate the inhibitory effect of ethyl gallate on nitric oxide production in LPS-stimulated RAW 264.7 cells. Results showed that ethyl gallate significantly inhibited NO production at 25 μM. PLoS One. 2018 Nov 28;13(11):e0207872
Rat basophilic leukemia humanized cell line RS-ATL8 10^-12 M to 10^-4 M 30 minutes To evaluate the inhibitory effect of Evatanepag on RS-ATL8 cell degranulation. Results showed Evatanepag inhibited hFcεRI-induced mast cell degranulation in a dose-dependent manner from 10^-12 M to 10^-8 M, with a maximum inhibition rate of 46%. Allergy Asthma Immunol Res. 2020 Jul;12(4):712-728
Human leukemic mast cell line LAD2 10^-7 M to 3×10^-4 M 2 hours 15 minutes To evaluate the inhibitory effect of Evatanepag on LAD2 cell degranulation. Results showed Evatanepag inhibited FcεRI-induced mast cell degranulation in a dose-dependent manner, with a maximum inhibition rate of 37.2%. Allergy Asthma Immunol Res. 2020 Jul;12(4):712-728

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice House dust mite-induced asthma model Intranasal administration 0.3 mg/kg or 3 mg/kg Once daily from day -1 to day 4 of sensitization To evaluate the protective effect of Evatanepag in a house dust mite-induced asthma model. Results showed 0.3 mg·kg^-1 dose significantly reduced airway hyperresponsiveness, while 3 mg·kg^-1 dose reduced airway mast cell activity by 48% (not statistically significant). Allergy Asthma Immunol Res. 2020 Jul;12(4):712-728

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.13mL

0.43mL

0.21mL

10.67mL

2.13mL

1.07mL

21.34mL

4.27mL

2.13mL

References

 

Historical Records

Categories